James A. Torchia

James A. Torchia

Auto-generated profile, based on publicly available information

James A. Torchia

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in Science Advances
Verified
Journal Article
Open access
JTJames A. Torchia
James A. Torchia
ATAlexander H. Tavares
Alexander H. Tavares
LCLaura S. Carstensen
Laura S. Carstensen
DCDa-Yuan Chen
Da-Yuan Chen
JHJessie Huang
Jessie Huang
GFGordon J. Freeman
Gordon J. Freeman
As severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) evolves to escape natural antibodies, it also loses sensitivity to therapeutic antibody drugs. By contrast, evolution selects for binding to ACE2, the cell-surface receptor required for SARS-CoV-2 infection. Consistent with this, we find that an ACE2 decoy neutralizes antibody-resistant variants, including Omicron, with no loss in potency. To identify design features necessary for in vivo activity, we compare several enzymatically inactive, Fc effector–silenced ACE2-Fc decoys. Inclusion of the ACE2 collectrin-like domain not only improves affinity for the S protein but also unexpectedly extends serum half-life and is necessary to reduce disease severity and viral titer in Syrian hamsters. Fc effector function is not required. The activity of ACE2 decoy receptors is due, in part, to their ability to trigger an irreversible structural change in the viral S protein. Our studies provide a new understanding of how ACE2 decoys function and support their development as therapeutics to treat ACE2-dependent coronaviruses.

20 November 2009 in Blood
Verified
Journal Article
Open access
RHRoch Houot
Roch Houot
MGMatthew J Goldstein
Matthew J Goldstein
HKHolbrook E Kohrt
Holbrook E Kohrt
JMJune H Myklebust
June H Myklebust
AAAsh A Alizadeh
Ash A Alizadeh
RLRonald Levy
Ronald Levy
Abstract 722